Dengue vaccine - Najit Technologies

Drug Profile

Dengue vaccine - Najit Technologies

Latest Information Update: 06 Jul 2016

Price : $50

At a glance

  • Originator Najit Technologies
  • Developer Najit Technologies; Oregon Health & Science University; Washington University
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 06 Jul 2016 Preclinical trials in Dengue (Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top